The Corporate Forum presents iBio, Inc. in Boston
The Corporate Forum is delighted to introduce iBio (NYSE MKT: IBIO) to a retail investor audience in Boston.
iBio is a biotechnology company that engages in the development and commercialization of vaccines and therapeutic proteins through its proprietary technology, the iBioLaunch platform.
Funded by the Bill Gates Foundation and DARPA, iBio's product portfolio consists of seasonal and H1N1 influenza vaccines for the seasonal influenza virus strains; pandemic avian influenza vaccine for the pathogenic avian influenza viruses; and therapeutic vaccines for human papilloma virus.
iBio also offers oral anthrax booster vaccine candidates and candidate plague vaccines. In addition, it provides therapeutic protein product candidates, including human alpha-galactosidase A for the treatment of Fabry disease; human C-1 esterase inhibitor for the treatment of hereditary angioedema; and human alpha-1 antitrypsin for treatment of disorders caused by a deficiency of alpha-1 antitrypsin. The company is headquartered in Newark, Delaware.